Citations

Clear

1792 citation(s) found for "Stephanie".

Evaluation of Posttreatment Follow-Up of Patients With Prostate Cancer Relative to the American College of Radiology's Appropriateness Criteria
Carter, Rickey E. , Karnes, R. Jeffrey , Port, John D. , Carlson, Stephanie K., Bender, Claire E., McDonald, Jennifer S. , Kawashima, Akira , Carter, Rickey E , Port, John D

Mayo Clinic

American Journal of Roentgenology | October 24, 2015 | Volume: 205 | Issue: 5 | Pages: 1008-1015

10.2214/ajr.14.13766 | PMID 26496548 Get It

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
Arai, Sally , Pidala, Joseph, Pusic, Iskra , Chai, Xiaoyu , Khera, Nandita , Palmer, Jeanne , Chen, George L. , Jagasia, Madan , Mayer, Sebastian , Wood, William A. , Hyun, Teresa S. , Inamoto, Yoshihiro , Storer, Barry E. , Shulman, Howard M., Sarantopoulos, Stefanie , Lee, Stephanie J. , Jaglowski, Samantha , Green, Michael , Miklos, David B. , Martin, Paul J. , Flowers, Mary E.D. , Chen, George , Lee, Stephanie J , Wood, William A

Mayo Clinic

Clinical Cancer Research | September 16, 2015 | Volume: 22 | Issue: 2 | Pages: 319-327

10.1158/1078-0432.ccr-15-1443 | PMID 26378033 Get It

Abstract Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrent malignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. Results: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%–43%] participants randomized to imatinib and 10 of 37 (27%; 95% CI, 14%–44%) randomized to rituximab. Six (17%; 95% CI, 7%–34%) patients in the imatinib arm and 5 (14%; 95% CI, 5%–29%) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-treated patients who had treatment success (P = 0.01), but not in imatinib-treated patients. Conclusions: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab. Clin Cancer Res; 22(2); 319–27. ©2015 AACR.
Association Between Atrial Fibrillation and Costs After Myocardial Infarction: A Community Study
Roger, Véronique L. , Mills, Roger M. , Weston, Susan A., Anderson, Stephanie S., Chamberlain, Alanna M. , Borah, Bijan J. , Mills, Roger M , Chamberlain, Alanna M

Mayo Clinic

Clinical Cardiology | September 7, 2015 | Volume: 38 | Issue: 9 | Pages: 548-554

10.1002/clc.22448 | PMID 26418757 Get It

ABSTRACTBackgroundThe authors sought to estimate incremental economic impact of atrial fibrillation (AF) and the timing of its onset in myocardial infarction (MI) patients.HypothesisConcurrent AF and its timing are associated with higher costs in MI patients.MethodsThis retrospective cohort study included incident MI patients from Olmsted County, Minnesota, treated between November 1, 2002, and December 31, 2010. We compared inflation‐adjusted standardized costs accumulated between incident MI and end of follow‐up among 3 groups by AF status and timing: no AF, new‐onset AF (within 30 days after index MI), and prior AF. Multivariate adjustment of median costs accounted for right‐censoring in costs.ResultsThe final study cohort had 1389 patients, with 989 in no AF, 163 in new‐onset AF, and 237 in prior AF categories. Median follow‐up times were 3.98, 3.23, and 2.55 years, respectively. Mean age at index was 67 years, with significantly younger patients in the no AF group (64 years vs 76 and 77 years, respectively; P < 0.001). New‐onset and prior AF patients had more comorbid conditions (hypertension, heart failure, and chronic obstructive pulmonary disease). After accounting for differences in baseline characteristics, we found adjusted median (95% confidence interval) costs of $73 000 ($69 000‐$76 000) for no AF; $85 000 ($81 000‐$89 000) for new‐onset AF; and $97 000 ($94 000‐$100 000) for prior AF. Inpatient costs composed the largest share of total median costs (no AF, 82%; new‐onset AF, 84%; prior AF, 83%).ConclusionsAtrial fibrillation frequently coexists with MI and imposes incremental costs, mainly attributable to inpatient care. Timing of AF matters, as prior AF was found to be associated with higher costs than new‐onset AF.
Sex Differences Research, Precision Medicine, and the Future of Women's Health
Miller, Virginia M. , Rocca, Walter A. , Faubion, Stephanie S.

Mayo Clinic

Journal of Women's Health | September 1, 2015 | Volume: 24 | Issue: 12 | Pages: 969-971

10.1089/jwh.2015.5498 | PMID 26325362 Get It

The National Institutes of Health's (NIH) commitment to improving health outcomes for women and men through rigorous science has been compromised by the lack of basic science evidence obtained from female animals. To correct this limitation, in June 2015 the NIH announced expectations that “sex,” as a biological variable, be included into research design and analysis in studies of vertebrate animals and humans (NOT-OD-15-102). Scientists must take the responsibility to implement this directive. However, in doing so, there is a risk that attention could be restricted to only studies of direct comparison between female/women and male/men. By contrast, understanding how sex influences health and disease needs to take a programmatic approach that includes the study of sex-specific conditions. A programmatic approach will assure the advancement of knowledge to improve women's health.
Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues
Minear, Mollie , Alessi, Stephanie A., Allyse, Megan , Michie, Marsha , Chandrasekharan, Subhashini , Allyse, Megan A

Mayo Clinic

Annual Review of Genomics and Human Genetics | August 31, 2015 | Volume: 16 | Issue: 1 | Pages: 369-398

10.1146/annurev-genom-090314-050000 | PMID 26322648 Get It

Noninvasive prenatal genetic testing (NIPT) for chromosomal aneuploidy involving the analysis of cell-free fetal DNA became commercially available in 2011. The low false-positive rate of NIPT, which reduces unnecessary prenatal invasive diagnostic procedures, has led to broad clinician and patient adoption. We discuss the ethical, legal, and social issues raised by rapid and global dissemination of NIPT. The number of women using NIPT is anticipated to expand, and the number of conditions being tested for will continue to increase as well, raising concerns about the routinization of testing and negative impacts on informed decision making. Ensuring that accurate and balanced information is available to all pregnant women and that access to NIPT is equitable will require policy guidance from regulators, professional societies, and payers. Empirical evidence about stakeholders' perspectives and experiences will continue to be essential in guiding policy development so that advances in NIPT can be used effectively and appropriately to improve prenatal care.
Genome-Wide Association Study of Prostate Cancer–Specific Survival
Szulkin, Robert , Whitington, Thomas, Aly, Markus , Grönberg, Henrik , Eeles, Rosalind A. , Easton, Douglas F. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Giles, Graham G. , Southey, Melissa C. , FitzGerald, Liesel M. , Henderson, Brian E., Schumacher, Fredrick R. , Haiman, Christopher A. , Sipeky, Csilla , Tammela, Teuvo L.J. , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Donovan, Jenny , Hamdy, Freddie C. , Pashayan, Nora , Stanford, Janet L. , Thibodeau, Stephen N. , McDonnell, Shannon K. , Schaid, Daniel J. , Maier, Christiane, Vogel, Walther , Luedeke, Manuel, Herkommer, Kathleen , Kibel, Adam S. , Lubiński, Jan , Kluźniak, Wojciech , Cannon‐Albright, Lisa , Brenner, Hermann , Herrmann, Volker, Holleczek, Bernd , Sellers, Thomas A. , Lim, Hui-Yi, Kaneva, Radka , Mitev, Vanio , Teixeira, Manuel R. , Paulo, Paula , Maia, Sofia , Pandha, Hardev , Michael, Agnieszka , Batra, Jyotsna , Clements, Judith A. , BioResource, on behalf of the Australian Prostate Cancer, Albanes, Demetrius, Andriole, Gerald L. , Berndt, Sonja I., Gapstur, Susan M. , Giovannucci, Edward L. , Ma, Jing , Mondul, Alison M. , Stampfer, Meir J. , Stevens, Victoria L. , Weinstein, Stephanie J. , Trichopoulou, Antonia , Bueno-de-Mesquita, Bas H., Tjønneland, Anne , Cox, David G. , Mæhle, Lovise, Schleutker, Johanna , Lindström, Sara , Karlsson, Robert , Kote‐Jarai, Zsofia , Key, Tim , Pharoah, Paul D.P. , Khaw, Kay‐Tee , Cybulski, Cezary , Park, Jong Y. , Slavov, Chavdar , Spurdle, Amanda B. , Kierzek, Andrzej , BioResource, on behalf of the Australian Prostate Cancer, Berndt, Sonja I. , Chanock, Stephen Jacob , Hunter, David J. , Kraft, Peter , Marchand, Loı̈c Le , Penney, Kathryn , Wiklund, Fredrik E. , Giles, Graham G , Teixeira, Manuel R , Eeles, Rosalind A , Southey, Melissa C , Tjønneland, Anne , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Cannon-Albright, Lisa A , Michael, Agnieszka , Brenner, Hermann , Batra, Jyotsna , Clements, Judith , Lubinski, Jan , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 25, 2015 | Volume: 24 | Issue: 11 | Pages: 1796-1800

10.1158/1055-9965.epi-15-0543 | PMID 26307654 Get It

Abstract Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). Results: We observed no significant association between genetic variants and prostate cancer survival. Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study. Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes. Cancer Epidemiol Biomarkers Prev; 24(11); 1796–800. ©2015 AACR.
Medium‐Chain Acyl‐CoA Dehydrogenase Deficiency in Adulthood: A Potential Diagnosis in a Patient with Mental Status Changes Suspected of Drug Toxicity
Randall, Morgan H. , Rolf, Cristin M., Gibson, Stephanie Mayfield, Hall, Patricia , Rinaldo, Piero, Davis, Gregory J., Hall, Patricia L

Mayo Clinic

Journal of Forensic Sciences | July 31, 2015 | Volume: 60 | Issue: 4 | Pages: 1101-1103

10.1111/1556-4029.12808 | PMID 26223762 Get It

AbstractMedium‐chain acyl‐CoA dehydrogenase (MCAD) deficiency is a rare but important component of the differential diagnosis for adults with a history of premortem mental status changes and the postmortem finding of hepatic steatosis. This case report describes a 30‐year‐old white man who, following a period of nausea and vomiting, was admitted to the hospital with sudden mental status deterioration followed rapidly by clinical deterioration and death. Treating physicians in this case suspected acute illicit drug toxicity with synthetic cathinones based on social history. Clinicians and medical examiners should be aware that the presentation, signs, and symptoms described may indicate an underlying inborn error of metabolism such as MCAD deficiency and take action accordingly.
Surveillance and Care of the Gynecologic Cancer Survivor
MacLaughlin, Kathy L. , Long, Margaret E. , Pruthi, Sandhya , Casey, Petra M., Faubion, Stephanie S.

Mayo Clinic

Journal of Women's Health | July 24, 2015 | Volume: 24 | Issue: 11 | Pages: 899-906

10.1089/jwh.2014.5127 | PMID 26208166 Get It

Background: Care of the gynecologic cancer survivor extends beyond cancer treatment to encompass promotion of sexual, cardiovascular, bone, and brain health; management of fertility, contraception, and vasomotor symptoms; and genetic counseling. Methods: This is a narrative review of the data and guidelines regarding care and surveillance of the gynecologic cancer survivor. We searched databases including PubMed, Cochrane, and Scopus using the search terms gynecologic cancer, cancer surveillance, and cancer survivor and reached a consensus for articles chosen for inclusion in the review based on availability in the English language and publication since 2001, as well as key older articles, consensus statements, and practice guidelines from professional societies. However, we did not undertake an extensive systematic search of the literature to identify all potentially relevant studies, nor did we utilize statistical methods to summarize data. We offer clinical recommendations for the management of gynecologic cancer survivors based on review of evidence and our collective clinical experience. Results: Key messages include the limitations of laboratory studies, including CA-125, and imaging in the setting of gynecologic cancer surveillance, hormonal and non-hormonal management of treatment-related vasomotor symptoms and genitourinary syndrome of menopause, as well as recommendations for general health screening, fertility preservation, and contraception. Conclusions: A holistic approach to care extending beyond cancer treatment alone benefits gynecologic cancer survivors. In addition to surveillance for cancer recurrence and late treatment side effects, survivors benefit from guidance on hormonal, contraceptive, and fertility management and promotion of cardiovascular, bone, brain, and sexual health.
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype–Phenotype Correlation
Rojnueangnit, Kitiwan , Xie, Jing , Gomes, Alicia , Sharp, Angela, Callens, Tom, Chen, Yunjia , Liu, Ying , Abbott, Mary‐Alice , Atkin, Joan, Babovic‐Vuksanovic, Dusica , Barnett, Christopher , Crenshaw, Melissa , Bartholomew, Dennis W., Basel, Lina, Bellus, Gary A. , Ben‐Shachar, Shay , Bialer, Martin G., Bick, David , Blumberg, Bruce , Cortés, Fanny, David, Karen L. , Destrèe, Anne , Rodríguez, Anna Duat , Earl, Dawn , Eswara, Marthanda, Ezquieta, Begoña, Frayling, Ian M. , Frydman, Moshe , Gardner, Kathy, Gripp, Karen W. , Hernández‐Chico, Concepción, Heyrman, Kurt, Ibrahim, Jennifer, Janssens, Sandra , Keena, Beth, Llano‐Rivas, Isabel , Leppig, Kathy, McDonald, Marie , Misra, Vinod K. , Mulbury, Jennifer, Narayanan, Vinodh , Orenstein, Naama, Galvin‐Parton, Patricia , Pedro, Hélio , Pivnick, Enikö K., Powell, Cynthia M. , Randolph, Linda M., Raskin, Salmo , Rubin, Karol, Seashore, Margretta R., Schaaf, Christian P. , Schultz, Meredith, Schorry, Elizabeth K. , Schnur, Rhonda E. , Siqveland, Elizabeth, Tkachuk, Amanda , Tonsgard, James H. , Upadhyaya, Meena , Verma, Ishwar C. , Wallace, Stephanie E , Williams, Charles A. , Zackai, Elaine H. , Zonana, Jonathan, Lázaro, Conxi , Claes, Kathleen , Korf, Bruce R. , Messiaen, Ludwine , Babovic-Vuksanovic, Dusica, Cochran, J. Nicholas , Escobar, Luis Fernando , Hernández-Chico, Concepción, Rosell, Jordi , Scheuerle, Angela E. , Martín, Yolanda , Legius, Eric , Claes, Kathleen B M , Lazaro, Conxi

Mayo Clinic

Human Mutation | July 14, 2015 | Volume: 36 | Issue: 11 | Pages: 1052-1063

10.1002/humu.22832 | PMID 26178382 Get It

Memory, executive, and multidomain subtle cognitive impairment
Toledo, Jon B. , Bjerke, Maria , Rozycki, Martin, Jack, Clifford R. , Weiner, Michael W. , Arnold, Steven E. , Reiman, Eric M. , Davatzikos, Christos , Shaw, Leslie M. , Trojanowski, John Q. , Initiative, For the Alzheimer's Disease Neuroimaging, Weiner, Michael, Aisen, Paul , Weiner, Michael, Petersen, Ronald, Jagust, William, Trojanowki, John Q., Green, Robert C., Saykin, Andrew J., Liu, Enchi , Green, Robert C., Montine, Tom, Petersen, Ronald, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , DeCarli, Charles, Jagust, William, Bandy, Dan, Foster, Norm, Reiman, Eric M., Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Potkin, Steven, Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald, Johnson, Kris , Doody, Rachelle S., Chowdhury, Munir , Bell, Karen L. , Leon, Sue, Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varon, Daniel, Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, R. Edward, Arnold, Steven E., Karlawish, Jason , Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Weiner, Myron, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Johnson, Keith A. , Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan N. , Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Saykin, Andrew J., Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Rogers, John, Kertesz, Andrew, Drost, Dick, Hernando, Raymundo, Sarrael, Antero, Schultz, Susan K. , Ponto, Laura L. Boles , Shim, Hyungsub , Smith, Karen E. , Relkin, Norman , Chaing, Gloria, Raudin, Lisa, Smith, Amanda , Fargher, Kristin, Raj, Balebail Ashok, Chen, Kewei , Initiative, For the Alzheimer's Disease Neuroimaging, Weiner, Michael, Weiner, Michael, Petersen, Ronald, Jagust, William, Toga, Arthur W. , Beckett, Laurel , Green, Robert C., Saykin, Andrew J., Morris, John C. , Green, Robert C., Petersen, Ronald, Donohue, Michael , Harvey, Danielle , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jagust, William, Koeppe, Robert A. , Foster, Norm, Reiman, Eric M., Mathis, Chet, Lee, Virginia M.‐Y. , Saykin, Andrew J. , Foroud, Tatiana , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Petersen, Ronald, Villanueva-Meyer, Javier E. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Shah, Raj C. , Duara, Ranjan , Varón, Daniel , Rusinek, Henry , Leon, Mony J. de , Arnold, Steven E., Wolk, David A. , López, Oscar L. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Stefanovic, Bojana , Feldman, Howard , Kertesz, Andrew, Rogers, John, Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Carlsson, Cynthia M. , Potkin, Steven G. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Saykin, Andrew J., Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Rogers, John, Kertesz, Andrew, Jack, Clifford R , Preda, Adrian , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | June 18, 2015 | Volume: 85 | Issue: 2 | Pages: 144-153

10.1212/wnl.0000000000001738 | PMID 26085606 Get It